HOW TO MANAGE POSTMENOPAUSAL OSTEOPOROSIS?BODY, J. J.Acta clinica belgica (English ed.). 2011, Vol 66, Num 6, pp 443-447, issn 1784-3286, 5 p.Conference Paper

Marqueurs du remodelage et ostéopathies malignesBODY, J. J.La Lettre du rhumatologue. 2008, Num 344, pp 39-39, issn 0761-5027, 1 p.Article

Traitement de l'ostéoporose post-ménopausique : actualités et perspectives = Update on treatment of postmenopausal osteoporosisBODY, J.-J.Revue médicale de Bruxelles. 2008, Vol 29, Num 4, pp 301-309, issn 0035-3639, 9 p.Conference Paper

Management of primary osteoporosisBODY, J.-J.Acta Clinica Belgica. 2002, Vol 57, Num 5, pp 277-283, issn 0001-5512, 7 p.Article

Traitement de l'ostéoporose: actualisation et perspectives = Treatment of osteoporosis: current status and perspectivesBODY, J.-J.Revue médicale de Bruxelles. 1994, Vol 15, Num 4, pp 282-286, issn 0035-3639Article

Tumor bone diseaseBODY, J.-J.Annales d'endocrinologie. 2006, Vol 67, Num 2, pp 166-172, issn 0003-4266, 7 p.Conference Paper

Ostéopénie et ostéoporose : Epidémiologie, coût, efficacité des méthodes diagnostiques et progrès thérapeutiques récents = Osteopenia and osteoporosis : Epidemiology, cost, effectivenessof diagnostic method and new therapeutical progressBODY, J.-J.Radiologie (Berlin). 1998, Vol 18, Num 2, pp 167-170, issn 0720-3322Article

Les hypercalcémies des tumeurs solides : physiopathologie et traitement = Hypercalcemia of solid tumors: physiopathology and treatmentBODY, J.-J.Revue française d'endocrinologie clinique, nutrition et métabolisme. 1992, Vol 33, Num 3, pp 201-208, issn 0048-8062Article

Cancer hypercalcemia: recent advances in understanding and treatmentBODY, J.-J.European journal of cancer & clinical oncology. 1984, Vol 20, Num 7, pp 865-869, issn 0277-5379Article

Bisphosphonates influence the proliferation and the maturation of normal human osteoblastsFROMIGUE, O; BODY, J. J.Journal of endocrinological investigation (Testo stampato). 2002, Vol 25, Num 6, pp 539-546, issn 0391-4097Article

Nutrition and quality of life in cancer patientsBODY, J. J; BORKOWSKI, A.European journal of cancer & clinical oncology. 1987, Vol 23, Num 2, pp 127-129, issn 0277-5379Article

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastasesBEUSELINCK, B; WOLTER, P; POPPEL, H. Van et al.British journal of cancer. 2012, Vol 107, Num 10, pp 1665-1671, issn 0007-0920, 7 p.Article

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubBODY, J.-J; BERGMANN, P; BOONEN, S et al.Osteoporosis international. 2010, Vol 21, Num 10, pp 1657-1680, issn 0937-941X, 24 p.Article

A prospective study on hyponatraemia in medical cancer patients : epidemiology, aetiology and differential diagnosisBERGHMANS, T; PAESMANS, M; BODY, J.-J et al.Supportive care in cancer. 2000, Vol 8, Num 3, pp 192-197, issn 0941-4355Conference Paper

Calcitonin deficiency in primary hypothyroidismBODY, J.-J; DEMEESTER-MIRKINE, N; BORKOWSKI, A et al.The Journal of clinical endocrinology and metabolism. 1986, Vol 62, Num 4, pp 700-703, issn 0021-972XArticle

Les biphosphonates et les douleurs métastatiques osseuses = Biphosphonates and bone metastasis painBODY, J. J.Oncologie (Paris). 2000, Vol 2, Num 4, pp 217-222, issn 1292-3818Article

Effects of secretory products of breast cancer cells on osteoblast-like cellsLACROIX, M; SIWEK, B; BODY, J. J et al.Breast cancer research and treatment. 1996, Vol 38, Num 2, pp 209-216, issn 0167-6806Article

Use of bisphosphonates in cancer patientsBODY, J. J; COLEMAN, R. E; PICCART, M et al.Cancer treatment reviews. 1996, Vol 22, Num 4, pp 265-287, issn 0305-7372Article

L'hyperparathyroïdie primaire: quand et comment la rechercher et la traiter ? = Primary hyperparathyroidism: diagnosis and managementBODY, J.-J.Revue médicale de Bruxelles. 2012, Vol 33, Num 4, pp 263-267, issn 0035-3639, 5 p.Conference Paper

Protein production by osteoblasts : modulation by breast cancer cell-derived factorsLACROIX, M; MARIE, P. J; BODY, J.-J et al.Breast cancer research and treatment. 2000, Vol 61, Num 1, pp 59-67, issn 0167-6806Article

Breast cancer cell response to calcitonin : Modulation by growth-regulating agentsLACROIX, M; SIWEK, B; BODY, J.-J et al.European journal of pharmacology. 1998, Vol 344, Num 2-3, pp 279-286, issn 0014-2999Article

Nasal human calcitonin for tumor-induced hypercalcemiaDUMON, J. C; MAGRITTE, A; BODY, J. J et al.Calcified tissue international. 1992, Vol 51, Num 1, pp 18-19, issn 0171-967XArticle

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaDUMON, J. C; MAGRITTE, A; BODY, J. J et al.Bone and mineral. 1991, Vol 15, Num 3, pp 257-266, issn 0169-6009Article

Calcitonin deficiency after radioactive iodine treatmentBODY, J. J; DEMEESTER-MIRKINE, N; CORVILAIN, J et al.Annals of internal medicine. 1988, Vol 109, Num 7, pp 590-591, issn 0003-4819, 2 p.Article

Nonspecific increases in plasma immunoreactive calcitonin in healthy individuals: discrimination from medullary thyroid carcinoma by a new extraction techniqueBODY, J.-J; HEATH, H. III.Clinical chemistry (Baltimore, Md.). 1984, Vol 30, Num 4, pp 511-514, issn 0009-9147Article